GlassScriptPhysician profile
J Kansal
NPI 1033289129
$3,605.59
in general payments reported to CMS, 2019-2025
16 companies · $762 in 2025
The $762 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $207 · 2021: $494 · 2022: $700 · 2023: $587 · 2024: $495 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,810.48 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,118.78 | 2021-2025 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $896.49 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $537.01 | 2019-2025 | Dupixent |
| Genzyme Corporation | $475.58 | 2019-2025 | |
| Amgen INC. | $83.37 | 2024-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $80.28 | 2020 | |
| Optinose US, INC. | $77.80 | 2019 | |
| Grifols USA, LLC | $57.74 | 2020-2021 | |
| Pfizer INC. | $55.06 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $46.83 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $36.84 | 2025 | |
| Kaleo, INC. | $35.72 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.01 | 2025 | Cuvitru |
| Lilly USA, LLC | $26.84 | 2025 | Ebglyss |
| Aimmune Therapeutics, INC. | $24.13 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $18.11 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Kansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.